Yannick A.
- Country
- France
- Department
- Service de Rhumatologie A
Research Overview
- Tulisokibart in Systemic Sclerosis-Associated Interstitial Lung Disease: A Randomized, Placebo-Controlled Trial of Safety and Efficacy
- A Phase II, randomised, placebo-controlled, double-blind, parallel-group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis
- Evaluation of Anifrolumab Efficacy and Safety in Systemic Sclerosis: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 130 of 279 partner sites.
Specializations
Systemic Sclerosis Specialization
The investigator demonstrates extensive involvement in treating systemic sclerosis (SSc), with particular emphasis on its various manifestations including diffuse cutaneous systemic sclerosis (dcSSc) and associated complications.
- Digital Ulcer Management
- Skin Fibrosis Treatment
- Novel Therapeutic Approaches
Pulmonary Complications
Specializes in addressing respiratory manifestations associated with rheumatic conditions, particularly interstitial lung disease (ILD). The investigator focuses on innovative treatments for systemic sclerosis-associated interstitial lung disease (SSc-ILD).
- Lung Function Assessment
- Combined Therapy Approaches
- Progressive ILD Management
Rheumatic Conditions
Conducts research in various rheumatic disorders, including polymyalgia rheumatica (PMR) and systemic autoimmune rheumatic diseases. The investigator explores treatments involving immunomodulation and targeted therapies.
- Autoimmune Disease Management
- Glucocorticoid Therapy
- Novel Biological Treatments
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.